Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: Two randomized, placebo-controlled, 2-year studies


      Objective: Our purpose was to investigate the long-term effects of raloxifene, compared with opposed and unopposed estrogen replacement therapy, on echocardiographic parameters of left ventricular systolic function in healthy postmenopausal women. A total of 157 women were studied in 2 randomized, double-blind, placebo-controlled, 2-year studies. Study design: In study I, 60 postmenopausal women who had undergone hysterectomy received daily raloxifene, 60 mg (n = 15); raloxifene, 150 mg (n = 15); conjugated equine estrogens (CEE), 0.625 mg (n = 15); or placebo (n = 15). In study II, 97 postmenopausal women who had not undergone hysterectomy received daily raloxifene, 60 mg (n = 24); raloxifene, 150 mg (n = 24); CEE, 0.625 mg, plus medroxyprogesterone acetate (MPA), 2.5 mg (n = 24); or placebo (n = 25). M-mode, quantitative 2-dimensional and Doppler echocardiographic measurements were performed at baseline and after 1 and 2 years. Results: Neither after 1 year nor after 2 years of treatment were echocardiographic parameters found to differ from baseline in both raloxifene groups, as well as in the unopposed CEE and the CEE/MPA groups, compared with the placebo group. Conclusion: Within 2 years of raloxifene treatment, no effect on echocardiographic parameters of left ventricular systolic function was found. Unopposed CEE or CEE/MPA also showed no effect. (Am J Obstet Gynecol 2002;186:729-36.)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chiamvimonvat V
        • Sternberg L
        Coronary artery disease in women.
        Can Fam Physician. 1998; 44: 2709-2717
        • Barrett-Connor E
        • Grady D
        Hormone replacement therapy, heart disease, and other considerations.
        Annu Rev Public Health. 1998; 19: 55-72
        • Hulley S
        • Grady D
        • Bush T
        • Furberg C
        • Herrington D
        • Riggs B
        • et al.
        Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.
        JAMA. 1998; 280: 605-613
        • Pines A
        • Fisman EZ
        • Levo Y
        • Averbuch M
        • Lidor A
        • Drory Y
        • et al.
        The effects of hormone replacement therapy in normal postmenopausal women: measurements of Doppler-derived parameters of aortic flow.
        Am J Obstet Gynecol. 1991; 164: 806-812
        • Pines A
        • Fisman EZ
        • Ayalon D
        • Drory Y
        • Averbuch M
        • Levo Y
        Long-term effects of hormone replacement therapy on Doppler-derived parameters of aortic flow in postmenopausal women.
        Chest. 1992; 102: 1496-1498
        • Voutilainen S
        • Hippelainen M
        • Hulkko S
        • Karppinen K
        • Ventila M
        • Kupari M
        Left ventricular diastolic function by Doppler echocardiography in relation to hormonal replacement therapy in healthy postmenopausal women.
        Am J Cardiol. 1993; 71: 614-617
        • Prelevic GM
        • Beljic T
        The effect of oestrogen and progestogen replacement therapy on systolic flow velocity in healthy postmenopausal women.
        Maturitas. 1994; 20: 37-44
        • Pines A
        • Fisman EZ
        • Shapira I
        • Drory Y
        • Weiss A
        • Eckstein N
        • et al.
        Exercise echocardiography in postmenopausal hormone users with mild systemic hypertension.
        Am J Cardiol. 1996; 78: 1385-1389
        • Taskin O
        • Gokdeniz R
        • Muderrisoglu H
        • Korkmaz ME
        • Uryan I
        • Atmaca R
        • et al.
        The effects of hormone replacement therapy on echocardiographic basic cardiac functions in postmenopausal women.
        Hum Reprod. 1998; 13: 2399-2401
        • Beljic T
        • Babic D
        • Marinkovic J
        • Prelevic GM
        The effect of hormone replacement therapy on diastolic left ventricular function in hypertensive and normotensive postmenopausal women.
        Maturitas. 1998; 29: 229-238
        • Sites CK
        • Tischler MD
        • Blackman JA
        • Niggel J
        • Fairbank JT
        • O'Connell M
        • et al.
        Effect of short-term hormone replacement therapy on left ventricular mass and contractile function.
        Fertil Steril. 1999; 71: 137-143
        • Fak AS
        • Erenus M
        • Tezcan H
        • Caymaz O
        • Oktay S
        • Oktay A
        Effects of a single dose of oral estrogen on left ventricular diastolic function in hypertensive postmenopausal women with diastolic dysfunction.
        Fertil Steril. 2000; 73: 66-71
        • Collaborative Group on Hormonal Factors in Breast Cancer
        Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer.
        Lancet. 1997; 350: 1047-1059
        • Goldstein SR
        Selective estrogen receptor modulators: a new category of therapeutic agents for extending the health of postmenopausal women.
        Am J Obstet Gynecol. 1998; 179: 1479-1484
        • Cummings SR
        • Eckert S
        • Krueger KA
        • Grady D
        • Powles TJ
        • Cauley JA
        • et al.
        The effect of raloxifene on risk of breast cancer in postmenopausal women—results from the MORE randomized trial.
        JAMA. 1999; 281: 2189-2197
        • Delmas PD
        • Bjarnason NH
        • Mitlak BH
        • Ravoux AC
        • Shah AS
        • Huster WJ
        • et al.
        Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
        N Engl J Med. 1997; 337: 1641-1647
        • Mijatovic V
        • Netelenbos JC
        • van der Mooren MJ
        • de Valk-de Roo GW
        • Jacobs C
        • Kenemans P
        Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogens on plasma homocysteine levels in healthy postmenopausal women.
        Fertil Steril. 1998; 70: 1085-1089
        • Mijatovic V
        • van der Mooren MJ
        • Kenemans P
        • de Valk-de Roo GW
        • Netelenbos JC
        Raloxifene lowers serum lipoprotein(a) in healthy postmenopausal women. A randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
        Menopause. 1999; 6: 134-137
        • Walsh BW
        • Paul S
        • Wild RA
        • Dean RA
        • Tracy RP
        • Cox DA
        • et al.
        The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial.
        J Clin Endocrinol Metab. 2000; 85: 214-218
        • Pearlman AS
        • Gardin JM
        • Martin RP
        • Parisi AF
        • Popp RL
        • Quinones MA
        • et al.
        Guidelines for optimal physician training in echocardiography. Recommendations of the American Society of Echocardiography Committee for Physician Training in Echocardiography.
        Am J Cardiol. 1987; 60: 158-163
        • Kessel H
        • Kamp O
        • Kenemans P
        • Mijatovic V
        • van Baal WM
        • Visser CA
        • et al.
        Effects of 15 months 17β-estradiol/dydrogesterone on systolic cardiac function using quantitative and Doppler echocardiography in healthy postmenopausal women.
        Am J Obstet Gynecol. 2001; 184: 910-916
        • Pines A
        • Fisman EZ
        • Averbuch M
        • Eckstein N
        • Drory Y
        • Bakshi R
        • et al.
        Left ventricular function during a short-term transdermal estradiol therapy in postmenopausal women: a double-blind placebo-controlled echocardiographic study.
        Eur Menopause J. 1996; 3: 53-59
        • Snabes MC
        • Payne JP
        • Kopelen HA
        • Dunn JK
        • Young RL
        • Zoghbi WA
        Physiologic estradiol replacement therapy and cardiac structure and function in normal postmenopausal women: a randomized, double-blind, placebo-controlled, crossover trial.
        Obstet Gynecol. 1997; 89: 332-339
        • Lee M
        • Giardina EG
        • Homma S
        • DiTullio MR
        • Sciacca RR
        Lack of effect of estrogen on rest and treadmill exercise in postmenopausal women without known cardiac disease.
        Am J Cardiol. 1997; 80: 793-797
        • Light K
        • Hinderliter A
        • West S
        • Grewen K
        • Steege J
        • Sherwood A
        • et al.
        Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women.
        J Hypertension. 2001; 19: 269-278